| 摘要 |
The patent application relates to chemical compounds with a basic structure selected from salicylic acid, acetylsalicylic acid, APHS (o-acetoxyphenylhept-2-inylsulfid), salen ligands, diflunisal, salsalate, benorylate, phenylalkanylcarbon acids (particularly fenoprofen, ibuprofen, ketoprofen, flurbiprofen, naproxen, tolmetin, sulindac, indomethacin, diclofenac, carprofen, etodolac, ketorolac), oxicam inhibitors (particularly Tenoxicam, Prioxicam, Meloxicam), anthranilic acids: (particularly mefenamic acid, meclofenamic acid), sulfonamides (particularly celecoxib and valdecoxib), methyl sulphones (particularly rofecoxib, etoricoxib, DuP697 (CAS 88149-94-4), NS398 (CAS 123653-11-2), flosulide (CGP28238), nimesulide, diaryl heterocyclene (particularly sodium parecoxib), propanamides (particularly parecoxib), butanzone (particularly phenylbutazone, oxyphenylbutazone), paracetamol, phenacetin, phenazone, dipyrone, amidopyrine, and esters and acid amides of the compounds mentioned, methotrexate, Br-R99219, trimethoprim, tipranavir, indinavir, ritonavir, JH-174 and NMB-006, thyronin, thyroxine and triiodothyronine, butylscopolamine bromide, clonidine, duloxetine, fenoterol, losartan, oxazepam, lorazepam, salbutamol, tiotropium bromide, atorvastatin, simvastatin, olanzapine, amlodipine, clopidogrel, sertraline, resveratrol, 1-Phenylpropan-2-amine and N-Methy-1-phenylpropan-2-amine, ephedrine, and the pharmaceutically acceptable salts, hydrates, solvents, and metal complexes of the compounds mentioned, wherein the basic structure is modified such that it comprises at least one cluster, preferably a cluster containing borate. The invention further relates to a method for the production and use thereof in pharmaceuticals, as catalysts, and as materials. |
